Worth reading
65In focus
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
838000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status report for Series 3 through Series 5 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clauses)
Who receives how much
838,000 new shares upon exercise of the Series 3 stock acquisition rights (0 shares for Series 4 and Series 5)
EVO FUND (issued on 29 December 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio under the exercise restrictions: 5.7% (838,000 shares / 14,813,400 shares)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥477 for Series 3, ¥564 for Series 4 and ¥651 for Series 5. Details of the exercise price adjustment clauses and the adjustment floor: not disclosed
Number of Stock Acquisition Rights
The total number issued was 12,000 rights for each series. As of the end of April 2026, the unexercised balance was 3,620 Series 3 rights, 12,000 Series 4 rights and 12,000 Series 5 rights
Procedures under the Corporate Code of Conduct
Report on compliance with the exercise restrictions under Article 434 of the Listing Regulations. The number of shares delivered across all series was 838,000, the number of listed shares as of the payment date for the issuance was 14,813,400, and the exercise ratio under the exercise restrictions was 5.7%
Most recent equity financing
Series 3 through Series 5 stock acquisition rights issued on 29 December 2025 (with exercise price adjustment clauses). Amount: not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status report for Series 3 through Series 5 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Number of shares to be issued or disposed of | 838,000 new shares upon exercise of the Series 3 stock acquisition rights (0 shares for Series 4 and Series 5) |
| Intended allottee | EVO FUND (issued on 29 December 2025) |
| Dilution Rate | Exercise ratio under the exercise restrictions: 5.7% (838,000 shares / 14,813,400 shares) |
| Total number of issued shares | 14,815,200 shares (as of the end of the month preceding the month covered) → Not disclosed |
| Exercise price | ¥477 for Series 3, ¥564 for Series 4 and ¥651 for Series 5. Details of the exercise price adjustment clauses and the adjustment floor: not disclosed |
| Number of Stock Acquisition Rights | The total number issued was 12,000 rights for each series. As of the end of April 2026, the unexercised balance was 3,620 Series 3 rights, 12,000 Series 4 rights and 12,000 Series 5 rights |
| Procedures under the Corporate Code of Conduct | Report on compliance with the exercise restrictions under Article 434 of the Listing Regulations. The number of shares delivered across all series was 838,000, the number of listed shares as of the payment date for the issuance was 14,813,400, and the exercise ratio under the exercise restrictions was 5.7% |
| Most recent equity financing | Series 3 through Series 5 stock acquisition rights issued on 29 December 2025 (with exercise price adjustment clauses). Amount: not disclosed |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the stock acquisition rights and compliance with the exercise restrictions.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.